days) and FFs (42 days) (P = 0.007). Matched subjects (n = 312; 104/group) were analyzed. Reconstruction success at 180 days for BWM, LTR, and FF was 69.2%, 91.3%, and 93.3%, and total costs per subject were $34,877, $35,220, and $53,492, respectively. FF cases tended to be longer (408 versus 50 and 85 minutes for BWM and LTR, respectively; P < 0.001), and FF patients had a greater length of stay (LOS) in the hospital (7 versus 2 and 5 days for BWM and LTR, respectively; P < 0.001). Readmissions (odds ratio, 1.58; 95% CL, 0.95-2.61) and reoperations (odds ratio, 1.46; 95% CL, 1.00-2.15) were greater for FF. Amputation rates were highest for BWM (n = 15; 14.4%) compared to LTR (n = 6; 5.8%) and FF (n = 4; 3.8%) (P = 0.017). Using conditional logistic regression models, predicted probabilities of success demonstrated that LTR, if achievable, provides great success at low cost. FF was most effective with large, traumatic wounds but at higher costs and longer LOS. BWM was least effective but successfully treated older, obese patients without exposed bone at low costs and decreased LOS.
BACKGROUND: Latissimus dorsi (LD) muscle flap has been widely used for autologous breast reconstruction. 1 Traditional open LD flap harvest requires a posterior donor site incision with a length of 15-45 cm. Although the scar can be camouflaged for women when wearing the bra, it tends to be long, frequently widens, and hypertrophies with time. 2 Therefore, a minimally invasive technique to harvest LD muscle flap via endoscopic approach has been developed. Despite continuous improvements in surgical techniques and technologies, 2-dimensional view and nonflexible instruments are limitations of endoscopic harvest of the LD muscle flap. 3 Meanwhile, a robotic-assisted LD muscle flap has been first introduced for autologous breast reconstruction after mastectomy. 4 The authors has demonstrated a modified robotic surgical technique using a transaxillary gasless technique for robot-assisted LD muscle flaps in 2012. 5 The purpose of this study was to introduce our 7-year experience with the robotic-assisted LD muscle flaps in autologous breast reconstruction.
PATIENTS AND METHODS:
Between October 2012 and February 2019, a total of 33 patients underwent autologous breast reconstructions using robotic-assisted LD muscle flap. Among 33 patients, 21 patients had Poland syndrome. Seven and 3 patients underwent robotic-assisted LD flap following immediate and delayed breast reconstruction after mastectomy, respectively. Two patients had capsular contracture of implant. Subjective assessment was performed to evaluate satisfaction of overall outcome, breast symmetry, and scar. Mean follow-up time was 29.8 ± 12.5 months (range, 3-61 months).
RESULTS:
All 33 flaps were successfully transferred without converting to open technique. As our experience with robotic-assisted LD flap increased steadily over the years, we have achieved improvements in surgical techniques and robotic instruments to comfort during surgery, optimize the results, and minimize complications and contour defects compared to the first time with robotic surgery. In addition, the time for robotic surgery system also markedly decreased after experience accumulation. Recently, the time for robotic docking and robotic surgery was about 30 and 60 minutes, respectively. At the last visit, patients' average grading of satisfaction of overall outcome, breast symmetry, and scar were 4.75 ± 0.23, 4.32 ± 0.63, and 4.88 ± 0.15, respectively. No serious complications such as flap loss were recorded for any patient.
CONCLUSION:
Autologous breast reconstruction using robotic-assisted LD muscle flap might be effective and safe. 
REFERENCES
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PURPOSE: Antifibrinolytic medications, such as tranexamic acid (TXA), have recently garnered increased attention in plastic surgery. Despite its ability to mitigate intraoperative blood loss and need for blood transfusion, there remains a paucity of research on TXA in breast reconstruction. The aim of this study was to investigate whether intravenous TXA reduces the risk of postoperative hematoma following immediate implant-based breast reconstruction.
METHODS:
A single-center retrospective cohort study was performed to analyze all consecutive patients undergoing immediate 2-stage IBR following mastectomy over 2 years (2015) (2016) . The incidence of postoperative hematomas and thromboembolic events among all patients was reviewed. The patients in the intervention group received 1,000 mg of intravenous TXA before mastectomy incision and 1,000 mg at the conclusion of the procedure. Fisher's exact test and the Mann-Whitney-Wilcoxon test were used. Multivariate logistic regression models were performed to study the impact of intravenous TXA after adjusting for possible confounders.
RESULTS:
A total of 868 consecutive breast reconstructions (499 women) were reviewed. Overall, 116 patients (217 breasts) received intravenous TXA, whereas 383 patients (651 breasts) did not. Patient characteristics and comorbidities were similar among the groups. Patients who received TXA were less likely to develop hematomas (n = 1; 0.46%) than patients who did not (n = 19; 2.9%) after controlling for age, hypertension, and type of reconstruction (prepectoral and subpectoral; P = 0.018). Adverse effects of intravenous TXA, including thromboembolic phenomena, were not observed. Multivariate analysis demonstrated that age and hypertension independently increase risk for hematoma.
CONCLUSION:
Intravenous TXA safely reduces risk of hematoma in IBR. Further prospective randomized studies are warranted to further corroborate these findings.
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